CLAIM AMENDMENTS

Please enter the following amendments without prejudice or disclaimer.

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (currently amended) A drug carrier system comprising a plurality of colloidal particles ~~said particles~~ having a core and a shell ~~and said particles~~ comprising ~~a~~ copolymer ~~molecules~~,

which copolymer comprises at least one A block and at least one B block different from the at least one A block,

wherein the at least one A block consists of a polymer unit of a first set of monomers and the at least one B block consists of a second set of monomers,

~~wherein~~ ~~characterized in that~~ the first set of monomers and the second set of monomers are selected ~~in such a way~~ so that polymers ~~only~~ consisting only of monomers of the first set and polymers consisting only of monomers of the second set are capable of forming an aqueous two-phase system, and

~~in that~~ wherein the A blocks in particles form the core and the B blocks in the particles form the shell.

2. (currently amended) The drug carrier system of claim 1, wherein said particles comprise[[s]] a micellar structure.

3. (currently amended) The drug carrier system of claim 1~~or 2~~, having intermolecular crosslinks between at least some of the A blocks in the same particle.

4. (currently amended) The drug carrier system of claim 1, ~~2 or 3,~~ having intermolecular crosslinks between at least some of the B blocks in the same particle.

5. (currently amended) The drug carrier system of ~~any one of the preceding claims~~ claim 1, further comprising a polymer consisting of monomers of the first set.

6. (currently amended) The drug carrier system of claim 5, having intermolecular crosslinks between at least some of the A blocks in the copolymer and at least some of the chains of the polymer consisting of monomers of the first set in the same particle.

7. (currently amended) The drug carrier system according to ~~any one of the preceding claims~~ claim 1, wherein the A block has a biodegradable backbone.

8. (currently amended) The drug carrier system ~~according to~~ of claim 3 ~~or claim 6~~, having biodegradable spacers between block A and at least some of the intermolecular crosslinks.

9. (original) The drug carrier system of claim 8, wherein the biodegradable spacers comprise a hydrolysable ester bond, a hydrolysable amide bond, or a hydrolysable carbonate bond.

10. (currently amended) The drug carrier system ~~according to any one of the preceding claims,~~ of claim 1, wherein the A block consists of a polymer unit of saccharides or derivatives thereof.

11. (original) The drug carrier system according to claim 10, wherein the saccharide is a dextran, optionally modified with an acrylic, a methacrylic or a hydroxyethylmethacrylic group.

12. (currently amended) The drug carrier system ~~according to any one of the preceding claims,~~ of claim 1, wherein the B block consists of a polymer unit of ethylene glycols.

13. (currently amended) The drug carrier system ~~according to any one of the preceding claims,~~ of claim 1, wherein the colloidal particles are substantially insoluble in an aqueous liquid at physiological conditions.

14. (currently amended) The drug carrier system ~~according to any one of the preceding claims,~~ of claim 1, wherein the colloidal particles have a mean particle size of between 5 nm and 50 μm.

15. (currently amended) The drug carrier system ~~according to any one of the preceding claims,~~ of claim 1, further comprising an active ingredient and preferably a pharmaceutically active ingredient.

16. (currently amended) A pharmaceutical composition comprising the colloidal drug carrier system ~~according to any one of the preceding claims,~~ of claim 1.

17. (currently amended) A block copolymer comprising at least one A block and at least one B block different from the at least one A block,

wherein the at least one A block consists of a polymer unit of a first set of monomers and the at least one B block consists of a second set of monomers,

~~characterized in that~~ wherein the first set of monomers and the second set of monomers are selected ~~in such a way~~ so that polymers only consisting of monomers of the first set and polymers only consisting of monomers of the second set are capable of forming an aqueous two-phase system, and

wherein the at least one A block comprises one or more crosslinkable groups.

18. The copolymer according to claim 16, having the structure A-B or A-B-A.

19. (currently amended) The copolymer of claim 17 ~~or 18~~, wherein the A block possesses a biodegradable backbone.

20. (currently amended) The copolymer ~~according to any one of claims 17-19~~ of claim 17, wherein a biodegradable spacer is present between the A block and at least some of the crosslinkable groups.

21. (original) The copolymer of claim 20, wherein the biodegradable spacer comprises a hydrolysable ester bond, a hydrolysable amide bond, or a hydrolysable carbonate bond.

22. (currently amended) The copolymer ~~according to any one of claims 17-21~~ of claim 17, wherein the A block consists of a block selected from the group consisting of native polysaccharides, modified polysaccharides, polyalkylene oxides, polyalkylene glycols, polyvinyl alcohol, polyvinylpyrrolidone, and proteins.

23. (original) The copolymer of claim 22, wherein A block is comprised of dextran units, optionally modified with acrylic, methacrylic or hydroxyethylmethacrylic groups.

24. (currently amended) The copolymer ~~according to any one of claims 17-23~~ of claim 17, wherein the B block is a polyethylene glycol block.

25. (currently amended) The copolymer ~~according to any one of claims 17-24~~ of claim 17, further comprising at least one block C which is different from the A block and the B block.

26. (currently amended) The copolymer ~~according to any one of claims 17-25~~ of claim 17, wherein the B block further comprises a ligand, such as a target-recognizing peptide, protein, antibody, or carbohydrate.

27. (cancel)

28. (cancel)

29. (currently amended) An aqueous composition comprising the copolymer ~~according to any one~~ of ~~claims 17-26~~ claim 17.

30. (original) The composition of claim 28 wherein polymers consisting of monomers of the first set and polymers consisting of monomers of the second set are present in an amount effecting a phase separation between a first aqueous phase rich in polymers consisting of monomers of the first set and a second aqueous phase rich in polymers consisting of monomers of the second set.

31. (original) The composition of claim 30, wherein the second aqueous phase forms the continuous phase of the two-phase system.

32. (currently amended) Method for the preparation of a drug carrier system comprising a plurality of colloidal particles, said method comprising the steps of:

(a) preparing an aqueous colloidal solution comprising micelles, said micelles being comprised of a block copolymer ~~according to any one of claims 16-25~~ of claim 17, and

(b) crosslinking at least same of the crosslinkable groups; wherein step (b) is carried out after step (a).

33. (original) The method of claim 32, wherein step (b) is carried out in the presence of an active substance.

34. (currently amended) Method for the preparation of a drug carrier system comprising a plurality of colloidal particles, said method comprising the steps of:

(a) preparing an aqueous two-phase system, said system comprising:

(aa) block copolymer ~~according to any one of claims 16-25~~ of claim 17;

(bb) polymer consisting of monomers of the first set;

(cc) polymer consisting of monomers of the second set; and

(dd) water;

wherein the relative amounts of polymer (bb), polymer (cc) and water are selected to induce a phase separation;

(b) crosslinking at least some of the crosslinkable groups; wherein step (b) is carried out after step (a).

35. (currently amended) The method of ~~any one of claims 32-34~~ claim 32, wherein the aqueous two-phase system comprises a further block copolymer as defined in claim [[1]] 17.

36. (original) The method of claim 35 wherein at least a part of the B blocks of the block copolymers comprises a target recognizing ligand, such as an antibody, peptide, protein, or carbohydrate.

37. (new) The drug carrier system of claim 6, having biodegradable spacers between block A and at least some of the intermolecular crosslinks.

38. (new) The method of claim 34, wherein the aqueous two-phase system comprises a further block copolymer as defined in claim 17.